Quantcast

Latest Mylan Inc. Stories

2014-05-09 08:26:49

PITTSBURGH, May 9, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that the company will present at the BofA Merrill Lynch 2014 Health Care Conference on Wednesday, May 14, 2014, in Las Vegas. The presentation is scheduled to begin at 11:20 a.m. PT. Interested parties can access a live webcast of the presentation via the investor relations section of Mylan's Web site at...

2014-05-01 08:34:57

Reaffirms 2014 Adjusted Diluted EPS Guidance Range of $3.25 - $3.60 PITTSBURGH, May 1, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced its financial results for the three months ended March 31, 2014. Financial Highlights -- Adjusted diluted EPS of $0.66 for the three months ended March 31, 2014 compared to $0.62 for the same prior year period, an increase of 6% -- Total revenues of $1.72 billion for the three months ended March 31, 2014 compared to...

2014-04-25 20:21:31

Mylan Seeks to Confirm Shared 180-Day Exclusivity PITTSBURGH, April 25, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has filed suit against the U.S. Food and Drug Administration (FDA), challenging the agency's decision regarding generic drug marketing exclusivity on Celecoxib Capsules, the generic version of Pfizer's Celebrex(®). FDA issued a decision holding that eligibility for 180 days of exclusivity is only available to an applicant who first filed a...

2014-04-18 20:21:09

PITTSBURGH, April 18, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that Supreme Court Chief Justice Roberts has denied Teva's application for an injunction seeking to prevent Mylan's launch of a generic version of Copaxone(®) pending the Supreme Court's decision on Teva's appeal. This is the second time that the Chief Justice has denied Teva's request for such an injunction. In March, the Supreme Court granted Teva's petition for certiorari seeking clarification of...

2014-04-16 16:30:46

PITTSBURGH, April 16, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched XULANE(TM) (Norelgestromin / Ethinyl Estradiol Transdermal System 150/35 mcg per day), the generic version of Janssen Pharmaceuticals Inc.'s ORTHO EVRA®* (Norelgestromin / Ethinyl Estradiol Transdermal System 150/35 mcg per day). This product is indicated for the prevention of pregnancy in women who elect to use a transdermal patch...

2014-04-15 12:30:09

PITTSBURGH, April 15, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that it and its partner Famy Care Ltd. have entered into a settlement and license agreement with Warner Chilcott Company, LLC, settling the parties' litigation in connection with Mylan's filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Norethindrone and Ethinyl Estradiol Chewable Tablets 0.8 mg/0.025 mg and Ferrous Fumarate Chewable Tablets. This...

2014-04-15 12:29:59

PITTSBURGH, April 15, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has launched Eszopiclone Tablets 1 mg, 2 mg and 3 mg, the generic version of Sunovion Pharmaceuticals Inc.'s Lunesta(®). Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of insomnia. Eszopiclone Tablets 1 mg, 2 mg, 3 mg had U.S. sales of approximately $851.8...

2014-04-15 08:29:35

OXFORD, England and PITTSBURGH, April 15, 2014 /PRNewswire/ -- Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, today announced that it has entered into a global licensing agreement with Mylan Inc. (Nasdaq: MYL), one of the world's leading global pharmaceutical companies, for its leading inhaled respiratory products, PSX1001 and PSX1050. PSX1001 and PSX1050, which are the first products to emerge from Prosonix's...

2014-04-11 08:24:31

PITTSBURGH, April 11, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that a federal district court has granted its request to enforce a settlement agreement between Endo Pharmaceuticals and Mylan settling patent litigation in connection with Mylan's filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Frovatriptan Succinate Tablets, 2.5 mg. This product is the generic version of FROVA(®), which is used to treat acute...

2014-04-08 16:23:32

PITTSBURGH, April 8, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it will host a conference call and live webcast on Thursday, May 1, 2014, at 11 a.m. ET, to review the company's financial results for the first quarter ended March 31, 2014. Mylan will release its financial results on May 1, before the market opens. The dial-in number to access the call is 800.514.4861 or 678.809.2405 for international callers. To access the live webcast, please log on to Mylan's...


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related